Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Oct 21 20:41:07 UTC 2019
by
admin
on
Mon Oct 21 20:41:07 UTC 2019
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
6NP3XSMIP3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
UCSF-FDA TRANSPORTAL |
SLC47A1
Created by
admin on Mon Oct 21 20:41:07 UTC 2019 , Edited by admin on Mon Oct 21 20:41:07 UTC 2019
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Rifamycin is an inhibitor of renal transporters organic anion transporter (OAT) 3, multidrug and toxin extrusion (MATE) 1, and MATE2-K transporters in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant inhibition of these transporters in vivo is unlikely.
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
|
TRANSPORTER -> INHIBITOR | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
|
INHIBITOR -> METABOLIC ENZYME | |||
|
|
INHIBITOR -> TRANSPORTER | |||
|
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
INHIBITOR
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
WEAK
IC50
|
||
|
|
INHIBITOR -> TRANSPORTER | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
|
INHIBITOR -> TRANSPORTER | |||
|
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
|
SUBSTRATE -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
Co€?administration of BIKTARVY with dofetilide may increase dofetilide plasma concentrations which can lead to serious and/or life threatening events.
CLINICALLY SIGNIFICANT
IC50
|
||
|
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|